The aim of our study was to evaluate, through the Eurocord and European Group for Blood and Marrow Transplantation (EBMT) registries, outcomes and risk factors for outcomes in adult patients who underwent single or double unrelated cord blood transplantation (UCBT) for myelodysplastic syndrome (MDS) or secondary acute myeloblastic leukemia (sAML). A total of 180 adults with MDS (n ¼ 39) or sAML (n ¼ 69) were analyzed. Risk factors for outcomes were analyzed using the Fine and Gray method and the Cox model. Median age was 43 (18-72) years. In all, 77 patients (71%) received a single UCBT. Myeloablative conditioning regimen (MAC) was given to 57 (53%) patients. Median numbers of nucleated and CD34 þ cells at freezing were 3.6 Â 10 7 and 1.1 Â 10 5 kg. At 60 days, cumulative incidence of neutrophil recovery was 78±4% and was independently associated with the number of CD34 þ cells per kg (41.1 Â 10 5 ; P ¼ 0.005) and advanced disease status (blasts o5% at time of UCBT, P ¼ 0.016). A 2-year non-relapse mortality (NRM) was significantly higher after MAC (62 vs 34%; P ¼ 0.009). A 2-year disease-free-survival (DFS) and overall survival (OS) were 30 and 34%, respectively. In multivariate analysis, patients with high-risk disease (blasts 45% and International Prognostic scoring system (IPSS) intermediate-2 or high in MDS) had significant poorer DFS (hazard ratio (HR): 1.76; P ¼ 0.047). In spite of high NRM, these data indicate that UCBT is an acceptable alternative option to treat adults with high-risk MDS or sAML, without a suitable human leukocyte antigen (HLA)-matched donor.
Introduction
Since the publication of encouraging results with unrelated cord blood transplantation (UCBT) in early 2000, this procedure has been used with increasing frequency in patients lacking an human leukocyte antigen (HLA)-matched donor. [1] [2] [3] The main advantages of UCBT include rapidity of availability and the possibility of using partially HLA-mismatched UCB units without high risk of graft vs host disease (GVHD). The limiting factor is an engraftment rate of around 70-90%, which is highly influenced by total nucleated and CD34
þ cell dose at UCB collection. 4 To overcome this obstacle, double UCBT has been successfully performed. 5 UCBT, initially reserved to children, has been more frequently used in adults because of the use of double UCBT. 6 For patients with acute leukemia, UCBT is currently accepted as an alternative source in patients lacking HLA-matched unrelated donor. In contrast, up to now, few data exist for patients with myelodysplastic syndrome (MDS). Patients with MDS or secondary acute myeloblastic leukemia (sAML) respond very poorly to chemotherapy and in higher risk patients, survival is below 10% at 2 years. 7-9 New medications such as demethylating agents have shown some hematological and survival improvements, [10] [11] [12] [13] but allogeneic hematopoietic stem cell transplantation (HSCT) remains indicated in high-risk patients aged o60 years.
14- 16 Unfortunately, only 40-50% of patients will have a suitable HLA-matched donor. UCBT has been used as an alternative for some patients lacking an adult donor. The aim of this study was to evaluate outcomes of adult patients reported to the Eurocord and European Group for Blood and Marrow Transplantation (EBMT) registries, who received single or double UCBT for MDS or sAML.
Materials and methods

Data collection and population
Eurocord is an International registry operating on behalf of the European Blood and Marrow Transplant (EBMT). Participation in this study was open to European and non-European centers performing UCBT. The median number of patients reported by each center was 1 (range: 1-16). A total of 27 patients have been previously published. 17 The study included all consecutive patients receiving UCBT between January 1997 and December 2008, who were 18 years old or more and were diagnosed with MDS or sAML at time of transplantation. Patients with AML secondary to MDS or therapy-related leukemia were included because their prognoses are usually considered similar. Patients who had received previous allogeneic hematopoietic stem cell transplant (HSCT) or a manipulated (ex vivo expansion) UCBT were excluded. Data regarding patient, disease and transplant characteristics and clinical outcomes were collected by standardized questionnaire for each UCBT recipient. For MDS, the questionnaire included MDS characteristics not only at diagnosis and at the time of UCBT, but also at worst status. A total of 108 patients met the above eligibility criteria.
Definitions
MDS and AML were classified according World Health Organization criteria. Patients with chronic myelomonocytic leukemia were also included in the study. The possible diagnoses for patients were: refractory anemia with or without ringed sideroblast, refractory cytopenias with multilineage dysplasia with or without ringed sideroblasts, refractory anemia with excess of blasts 1 (5-10%) and 2 (11-19%) , unclassifiable MDS, MDS associated with isolated 5qÀ, chronic myelomonocytic leukemia and AML. Classification and calculation of International Prognostic scoring system (IPSS) were performed at the time of diagnosis, worse status and transplantation. Cytogenetic classification was defined according to the Medical Research Council classification for AML 18 and the IPSS score for MDS. 19 Secondary acute leukemia was either transformed from MDS or therapy-related AML. At the time of UCBT, patients were classified as having high-risk disease if they had AML not in first or second remission or MDS with intermediate-2 or high IPSS score and disease with 45% blasts in bone marrow. Worst status of MDS was defined as either transformation into AML or the highest documented bone marrow blast count between diagnosis and UCBT. Donor-recipient HLA compatibility was determined by serology level typing for HLA-A and -B and by high-resolution allele level typing for HLA-DRB1. Transplants were classified as HLA mismatched with 1, 2, 3 or 4 differences if disparities were detected in HLA-A, -B or -DRB1.
The date of neutrophil engraftment was defined as the first of 3 consecutive days with neutrophil counts 40.5 Â 10 9 /l. Platelet engraftment was defined as the first of 7 consecutive days with platelet counts 420 Â 10 9 /l without transfusion. Primary graft failure was diagnosed when the neutrophil engraftment end point was not reached by day 60 or when a second transplant for non-engraftment was performed.
Determination of the comorbidity score was assigned using an HSCT-specific comorbidity index. 20 GVHD was diagnosed and graded according to standard criteria. 21, 22 Relapse was defined on the basis of morphological evidence of MDS or AML in bone marrow or in tissue or organ (chloroma).
Statistical analysis
The end points were engraftment, acute GVHD (aGVHD), relapse, overall survival (OS), event-free survival and nonrelapse mortality (NRM). All time-to-event data were calculated from the date of transplantation to the date of the event or last follow-up, whichever occurred first. NRM was defined as death without relapse and was analyzed in a competing risk setting, with relapse being treated as the competing event. Engraftment and acute and chronic GVHD were also analyzed in a competing risk setting, with death as competing events.
The cumulative incidences (CIs) of engraftment, acute and/or chronic GVHD, relapse and NRM were estimated using the Gray method. The probabilities of OS and event-free survival were estimated using the Kaplan-Meier method. 23 Covariates considered were age, diagnosis at the time of UCBT (MDS, AML), disease risk (high risk, low risk), period of transplant (1998-2005 vs 2006-2008) , recipient cytomegalovirus serostatus, median number of nucleated cells infused, conditioning regimen (reduced intensity conditioning regimen (RIC) or myeloablative conditioning regimen (MAC)), recipient gender, GVHD prophylaxis (cyclosporine plus steroids vs cyclosporine plus mycophenolate), use of antithymoglobulin before UCBT, number of UCB units (single vs double), median time from diagnosis to UCBT, HLA disparity, number of total nucleated and CD34 þ cells collected and infused. Multivariate models for outcomes were performed using the Fine and Gray method 24 for engraftment, acute and chronic GVHD, relapse and NRM and using the Cox model 25 for OS and DFS. Multivariate models were constructed using a forward selection procedure and only variables that attained a P-value p0.10 in univariate analysis were entered in the final model. All tests were two-sided. Statistical analyses were performed with SPSS 15.0 statistical software (SPSS, Chicago, IL, USA), Splus 6.1 (MathSoft, Seattle, WA, USA).
Results
Patient, disease and donor characteristics
Median patient age was 45 years (range, 18-72); 45 (42%) were men and 74 (69%) had positive cytomegalovirus serology before transplantation. Disease characteristics are shown in Table 1 . Table 2 . MAC consisted of cyclophosphamide with either total body irradiation (TBI) 46 Gy (n ¼ 20) or busulfan 48 mg/kg (n ¼ 12). RIC was based on fludarabine in all but three patients combined with low-dose TBI (p2 Gy) in 33 (65%) patients. A total of 49 (86%) MAC patients and 18 (35%) RIC patients also received antithymoglobulin. In all, 11 (51%) MAC patients and 41 (72%) RIC patients received GVHD prophylaxis consisting of cyclosporine and mycophenolate. UCBT characteristics are shown in Table 2 .
Engraftment
The CI of neutrophil recovery was 78±4% at 60 days after UCBT with a median time to achieve more than 0.5 Â 10 9 /l neutrophils of 23 (6-51) days. In univariate analysis, neutrophil recovery was decreased in patients (1) for whom time from diagnosis to UCBT was 49.5 months (69±6% vs 87±5%; P ¼ 0.02), (2) who received o1.1 Â 10 5 CD34 þ cells/kg (67±7% vs 86±6%; P ¼ 0.002) and (3) who had 45% blasts in the bone marrow at the time of UCBT (67 ± 7% vs 86 ± 5%; P ¼ 0.01). Patients who received RIC had similar engraftment than those who received MAC. In multivariate analysis, bone marrow blasts and number of CD34 þ cells infused were associated with increased neutrophil recovery (blasts o5%, hazard ratio (HR): 1.91, 95% confidence interval (95% CI): 1.13-3.24, P ¼ 0.016; CD34 þ 41.1 Â 10 5 cells per kg, HR: 2.02, 95% CI: 1.23-3.31, P ¼ 0.005). Cumulative incidence of platelet recovery was 50 ± 5% at a median time of 50 days (9-348).
Acute and chronic GVHD
The CI of grade II, III or IV aGVHD at day 100 was 26 ± 4%. Severe aGVHD (III and IV) occurred in 12 (11%) patients. The CI of aGVHD at day 100 was 30 ± 5% and 17 ± 7% for single and double CBT recipients, respectively (P ¼ 0.16). Patient age (age o43 years, CI: 26 ± 6%; age 443 years, CI: 27 ± 6%) and type of conditioning regimen (RIC CI: 28±6%; MAC CI: 25 ± 6%) were not statistically associated with aGVHD. In a multivariate analysis, none of the factors studied influenced the risk of aGVHD. Among patients who survived more than 100 days, chronic GVHD was observed in 19 patients; it was limited in 9 (47%) and extensive in 10 (53%) patients. The CI of 2-year chronic GVHD was 42±8%.
NRM and relapse
A 2-year CI of NRM was 49±5%. Results of the univariate analysis are listed in Table 3 . In multivariate analysis, RIC (HR: 0.42; 95% CI: 0.24-0.76; P ¼ 0.003) and shorter time from diagnosis to UCBT (o9.5 months) were associated with lower NRM (HR: 0.54; 95% CI: 0.31-0.94; P ¼ 0 .03). Among patients who received a MAC, those who received TBI had higher NRM (84±8% vs 53±9%; P ¼ 0.065). TBI did not influence NRM in patients who received a RIC. Antithymoglobulin did not increase NRM. CIs of NRM by the type of conditioning regimen (RIC or MAC) are shown in Figure 1a .
A 2-year CI of relapse was 21±4%. In multivariate analysis, risk factors associated with increased relapse incidence were RIC (HR: 2.45; 95% CI: 1.01-5.9; P ¼ 0.045) and high-risk disease (HR: 3.96; 95% CI: 3.95-12.44; P ¼ 0 .028).
OS and disease-free survival
The 2-year OS and DFS were 34 ± 5% and 30 ± 5% (Figure 1b) . Table 3 lists the univariate analysis for DFS. In multivariate analysis, the only risk factor associated with better DFS was lower disease risk at the time of UCBT (HR: 0.57; 95% CI: 0.32-0.99; P ¼ 0.047). There was a trend of improved DFS when the number of CD34 þ cells collected per kg was higher than 1.1 Â 10 5 (HR: 0.64; 95% CI: 0.39-1.06; P ¼ 0.081). In all, 20 patients died of relapse, infections were the main cause of death in 24 patients and were associated with GVHD in 9 or rejection in 4; hemorrhage was the cause of death in 5, respiratory failure in 4, multiorgan failure in 3 and other causes in 4 patients. of patients who received UCBT for MDS or sAML. DFS was 30%, which appears to be comparable to DFS after HSCT using other types of donors in large multicentric studies in high-risk MDS patients. 16, 27 In our study, early and late outcomes were Table 3 Risk factors for 2-year non-relapse mortality and event-free survival Non-relapse mortality ± s.d.
P-value
Disease-free survival ± s.d. Unrelated cord blood transplantation for myelodysplasia M Robin et al associated with the number of CD34 cells infused, type of conditioning regimen, the time from diagnosis to transplantation and, importantly, disease status at UCBT. The advantage of our study is the relatively high number of patients included and the possibility to perform a risk factor analysis. However, as UCBT is not frequently performed in MDS patients, we analyzed a relatively heterogeneous group of patients receiving single or double UCBT following RIC or MAC performed in 47 centers. Currently, UCBT for MDS represents the minority of UCBT indications and consequently, a lot of participating transplant centers performing few transplants for MDS were included. Of note, MDS patients in this study were rigidly selected: they were relatively young, with relatively low weight and an aggressive disease, including transformation into acute leukemia in more than half of the patients, and in sufficiently good general health to undergo allogeneic transplantation.
Non-engraftment and delayed immune recovery are possible risks that currently limit indications for performing UCBT. A recent study has shown that neutrophil engraftment was decreased in children with MDS as compared with children with acute leukemia receiving UCBT. 28 In our study, the CI of neutrophil engraftment was 78% and it was associated with CD34 þ cell dose and blast count at the time of UCBT. A CD34 þ cell dose higher than 1.1 Â 10 6 /kg was the threshold found in our study associated with engraftment, in concordance with previous studies. 29, 30 One could argue that the use of double cord blood transplantation could increase the probability of engraftment; however, this was not observed in our study. In fact, CD34 cell dose in double UCBT was equivalent to those in single UCBT, thus reflecting that double UCB grafts were used to overcome the lower cell dose contained in a single unit.
As expected, after UCBT, the CI of aGVHD was low. In contrast to a recent report, 31 patients who received double UCBT were not at greater risk for developing GVHD but these results should be interpreted with caution as the first double UCBT in this study was performed in 2001 and transplantation practices may have changed over time. For example, GVHD prophylaxis consisted of cyclosporine plus steroids in the majority of single UCBT recipients and cyclosporine plus mycophenolate in the majority of double UCBT recipients. Antithymoglobulin use before transplantation had no impact on GVHD occurrence (data not shown).
NRM remains important in UCBT and the most frequent cause of death is infection. Indeed, immune reconstitution is slower than in matched related donor transplanted patients, and infections are important complications. 32 In our study, time elapsed from diagnosis to UCBT and MAC increase were significant independent risk factors for NRM. A long delay before transplantation is often associated with multiple treatments and transfusions, increasing the risk of organ failure, infection, iron overload or more advanced disease. Disease duration before transplantation or iron overload has been regularly found to increase NRM and sometimes decrease survival in bone marrow or peripheral blood transplant recipients. [33] [34] [35] [36] Our study confirmed that RIC before UCBT is associated with a reduction in NRM, as observed in unrelated HSCT recipients. 36 Despite poorer general conditions and high-risk MDS, patients who received RIC had decreased NRM and a trend toward better DFS. The increased risk of relapse observed after RIC did not translate into poorer survival in our study despite a high proportion of patients with advanced disease. Furthermore, high-risk patients who received MAC had no survival advantage compared with high-risk patients who received RIC (data not shown). High-dose TBI appeared to result in particularly high NRM.
The most important risk factor for DFS was disease risk at the time of transplantation. These results raise the issue of pretransplantation treatment to reduce disease tumor burden without postponing transplantation, which increases NRM. No randomized study exists to assess the role of chemotherapy before transplantation. New drugs such as demethylating agents are now widely used in MDS patients but very few data are currently available to analyze their impact before allogeneic transplantation. 37 Our results indicate that although it is better to transplant MDS patients with less active disease, patients who transform into secondary AML may still benefit from UCBT if they have achieved remission before transplantation. The Markov decision model in MDS patients with an HLA-identical sibling donor has shown that patients had a life expectancy advantage if they were transplanted before the AML occurrence, 38 but no such data exist for transplantation from an unrelated donor.
Our study shows that UCBT can be used in high-risk MDS patients. No data are currently available to determine whether Figure 1 (a) Cumulative incidence of non-relapse mortality by conditioning regimen. Black line represents cumulative incidence of non-relapse mortality after MAC and dotted line represents cumulative incidence of non-relapse mortality after reduced intensity conditioning regimen. (b) Disease-free survival estimation by risk disease group. Black line represents disease-free survival in patients with lower risk disease (AML in remission, MDS with o5% blasts). Dotted line represents disease-free survival in patients with higher risk disease.
Unrelated cord blood transplantation for myelodysplasia M Robin et al a mismatched unrelated donor is better or worse than UCBT in MDS adults, but HSCT remains the only curative treatment in advanced MDS patients. In acute or chronic leukemia, transplantation from an HLA-matched or one HLA allelemismatched unrelated donor is associated with 5-10 and 10-15% lower survival rates, respectively, when compared with transplantation from an HLA-matched sibling donor, despite high resolution HLA typing. 39, 40 With respect to the source of unrelated stem cells, HLA-mismatched bone marrow or cord blood transplants have been shown to give similar outcome in adults with acute leukemia.
2 Furthermore, outcomes with cord blood transplantation have been reported to be similar to that of HLA-matched bone marrow by Rocha et al. 3 but this was not confirmed by Laughlin et al. 2 In patients with MDS, DFS appears to be similar to that achieved using other unrelated hematopoietic stem cell sources, but comparative studies are required to better determine the role of UCBT for this group of patients.
